Towards a Consensus Potency Assay for Mesenchymal Stromal Cells: A Matrix Analysis of Cell Source, Donor Variability, and Inflammatory Stimuli to Refine Surrogate Markers of Immunomodulation
May 2019
in “
Cytotherapy
”
mesenchymal stromal cells immunomodulation ATIR101 T-cell immunotherapy haploidentical hematopoietic stem cell transplantation haplo-HSCT graft-versus-host disease GVHD autologous stem cell interventions Australian Therapeutic Goods Administration TGA stem cell therapy immune therapy stem cell transplant autologous stem cells
Studysummary In this study, only a subset of proposed biomarkers universally responded to priming in mesenchymal stromal cells, suggesting limited utility for standardized potency assays across different MSC types and conditions.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on isct-cytotherapy.org →